Studies myasthenia gravis patients in China to improve diagnosis and track disease course
Follows people with myasthenia gravis over time, testing biomarkers and omics data.
Plain-language title generated from the registry record
Registry title: Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China
Key facts
- Where
- Shanghai, ChinaSee the 4 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 0 and 90 years old?
Source: NCT04535843, who can take part
Where in China
- Children's Hospital Of Fudan UniversityShanghai, ChinaTaking people
- Huashan HospitalShanghai, ChinaTaking people
- Obsterics and Gynecology Hospital of Fudan UniversityShanghai, ChinaTaking people
- Shanghai Chest HospitalShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Huashan Hospital
- Trial code
- NCT04535843
- Record updated
- 28 May 2025
- Original description
The present study is a prospective cohort study aiming to improve the clinical capacity in the diagnosis and natural history of Chinese patients with myasthenia gravis (MG). 300 MG patients are planned to recruit, document and prospectively follow up. Management of screening test and cohort manifestation are studied.Read full original descriptionShow less
Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China
The present study is a prospective cohort study aiming to improve the clinical capacity in the diagnosis and natural history of Chinese patients with myasthenia gravis (MG). 300 MG patients are planned to recruit, document and prospectively follow up. Management of screening test and cohort manifestation are studied.
Inclusion: fluctuating muscle weakness and fatigability, along with one of the below:; more than 10% amplitude decrement in low frequency repetitive nerve stimulation,less than 10% amplitude increment in high frequency repetitive nerve stimulation; anti-AChR or MuSK antibody positivity; positive to the neostigmine test; understanding and assigning the informed consent form, and having a good compliance with the follow up.
Exclusion: excluding the possible diagnosis of Lambert-Eaton syndrome, congenital myasthenia syndrome,botulism injection, chronic progressive extraocular ophthalmoplegia, etc; poor compliance to the follow up.